Clinical Trial

Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-05; most recent amendment 2025-07-01.
Status change: Not Yet Recruiting → Recruiting 2024-09-23
Trial Details
NCT Number NCT05860569
Lead Sponsor GeneCradle Inc
Conditions Hypertriglyceridemia, Familial
Enrollment 7 participants
Start Date 2024-09-20
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-03